

European College of Neuropsychopharmacology ECNP Research & Scholarship Foundation

Annual report 2018

~

<u>. O</u>

稟

Contents

About ECNP

President's

Overview of

- Education

- Science - Outreach

Treasurer's - Financial State

Executive Di

Report of th

Governance

This report covers two legally autonomous entities: the European College of Neuropsychopharmacology, a Swiss-constituted member society (hereafter ECNP Association); and the Netherlands-based ECNP Research and Scholarship Foundation (hereafter ECNP R&S).

or "the College."

ANBI

)	4
Introduction	6
Activities	8
	9
	12
	14
Report ements	16 18
irector's Report	23
ne External Review Board	24
	26

For the purposes of simplicity they are here collectively referred to as "ECNP"

Both ECNP Association and ECNP R&S are public-interest-serving entities (algemeen nut beogendeinstellingen – ANBI) under Dutch tax law.

About ECNP

ECNP is an independent European scientific association that exists to promote high-quality experimental and clinical research in applied and translational neuroscience with a view to stimulating the development of better treatments for those suffering disorders of the brain.

Our mission: to advance the science of the brain, promote better treatment and enhance brain health.

- More than 20 scientific meetings held every year
- Spanning all aspects of scientific, educational, and regulatory dialogue
- Bringing together researchers and clinicians from over 100 countries for fruitful scientific exchange
- 300 young scientists trained every year
- Paid for by ECNP
- A major international journal European Neuropsychopharmacology

Why we are here

By promoting new and better treatments for disorders of the brain ECNP aims to reduce the prevalence of these diseases and to alleviate the enormous suffering they cause.



Proportion of Europeans who suffer from a mental disorder annually

38%

(Eur Neuropsychopharmacol 2011)¹

Number of premature deaths among people aged 25-64 due to mental health problems and suicide across Europe

50,000

(OECD/EU 2018)²

- ______-

Number of deaths caused every year in Europe by brain disorders

1.2 million

(OECD/EU 2018)²



Reduction of life expectancy due to severe mental disorders

> **10 to 25 years**

Proportion of mental disorders that start before the age of 24



Total cost per annum of disorders of the brain to Europe

4% of GDP

(OECD/EU 2018)²

 H.-U. Wittchen, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018.

 Health at a Glance: Europe 2018. State of Health in the EU Cycle. http://www.oecd. org/health/health-at-a-glance-europe-23056088.htm

3) T. Paus, M. Keshavan, J. N. Giedd. Why do many psychiatric disorders emerge during adolescence? Nat. Rev. Neurosci. 2008; 9.12: 947-578

 Premature death among people with severe mental disorders. https://www. who.int/mental_health/management/ info_sheet.pdf

President's introduction

2018 was another year of remarkable activity and achievement for ECNP. In terms of its contribution to building the field and supporting the cause of applied and translational neuroscience in Europe, ECNP continues to lead the way.

> No other independent, non-governmental organisation in Europe connects more neuroscientists, psychiatrists, psychologists and neurologists, trains more early career scientists, supports more research networks, or confers more awards. It is a record of which we are extremely proud.

ECNP has been able to do this, in the first instance, because of the extraordinary level of commitment and engagement from hundreds of volunteers dedicating collectively thousands of hours of their time, as well as their ideas, energy, enthusiasm and verve. ECNP would not exist without them.

ECNP is also fortunate in having a strong capital position, and these reserves have been critical in allowing the College to maintain the breadth and momentum of its activities. We owe these reserves to the foresight, acumen and restraint of previous executive committees, and we are acutely aware of the responsibilities that come with them. The following report aims to demonstrate the care and seriousness with which the College is discharging those responsibilities – both to maximise the use of ECNP's resources and to ensure their long-term sustainability.

For all its dynamism, however, ECNP remains a small organisation – small in absolute terms, and small relative to the problems ECNP exists to address. Success is measured by impact. And having an impact requires rigorous focus. The last three years have been marked by an ongoing programme of assessment and realignment to ensure the College's resources are concentrated as efficiently as possible on the areas of greatest urgency and need. The priority has been to target issues that are of high relevance to our user group, region-wide in their scope and implications, and on which ECNP can make a meaningful impact. **Education.** Translational neuroscience mediates between better defined disciplines in basic neuroscience on the one side and clinical psychiatry and neurology on the other. The field's educational infrastructure has, as a consequence, always been less well developed. Addressing this gap, with translational education for researchers and neuroscience-informed training for clinicians, especially as it applies to the use of medicines, remains a critical priority.

Science. Propagating excellent science remains fundamental to the ECNP mission, not just amongst scientists to stimulate new and better research, but to clinicians, to encourage more scientifically informed treatment and, ultimately, better patient outcomes. Closely allied is the College's role as a facilitator of networks to connect researchers across the region and leverage Europe's scientific scale and depth to help address the biggest research questions.


Outreach. ECNP's independent and non-aligned status allows it to function as a connector between the field's various stakeholders in the academy, industry, regulatory bodies and the patient community. This platform function is vital to ECNP's role as facilitator of cross-talk and awareness-raising, part of its larger mission to support neuroscience across the treatment lifecycle.

The recent re-emergence of early phase clinical trials of drugs with different mechanisms of action, as well as the entry of new drugs on to the market, allows some cautious optimism that the problems that have beset the field in the last ten years, significantly impeding the development of new treatments, are beginning to be overcome. ECNP will continue to support these developments. Our mission is also taking us into new areas of science in the search for new treatment horizons, including genomics, proteomics and the digital revolution in diagnostics and therapeutics. These are exciting times in the field. ECNP has never been more needed.

Celso Arango President




Overview of activities



Education

Developing the next generation of European research and clinical leaders is a longstandingECNP priority, and a major focus of the College's resources. Stimulating translational research, promoting the best-practice use of treatments, providing methods training, assisting with career development, and encouraging early career scientists from European developing-economy countries are critical goals.



ECNP Workshop for Junior Scientists in Europe 15-18 March 2018, Nice, France

Three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.

- 95 participants from 23 countries
- 11 speakers from 5 countries, including the United States
- Keynote lecture by Sarah-Jayne Blakemore, United Kingdom
- 8 junior scientists funded to speak at the 31st ECNP Congress, with 12 poster presenters receiving a € 500 Travel Award to attend the ECNP Congress

Organisation, facilities, registration, tuition, accommodation and food provided by ECNP R&S.

"Besides discussing my results it was a great opportunity to meet and connect to lots of different researchers from various subfields of neurosciences coming from countries all over Europe."



"This is a fundamental course for junior scientists . . . Professor Vieta and all the speakers had an incredibly effective way to both capture our attention and to teach us something that is not learnable in books."

"Thank you very much for the opportunity to participate in ECNP School. It was a great experience. A great place, an excellent training program, wonderful food. A rare opportunity to get so many impressions and knowledge at the same time!"

ECNP WORKSHOP

ECNP Workshop on **Clinical Research Methods**

7-9 November 2018, Barcelona, Spain

Three days of training on research methodology and critical approaches to the scientific literature for early career scientists.

- 147 applications, 38 participants from 28 countries
- 12 participants from 10 developingeconomy countries
- 10 faculty

Organisation, facilities, registration, tuition. accommodation and food provided by ECNP R&S.

Methods training Specialist training in the theory and practice of pharmacological

Clinical training I

provided by ECNP R&S.

ECNP School of

24 countries

Neuropsychopharmacology

A week-long course covering the

24-29 June 2018, Oxford, United Kingdom

fundamentals of neuropsychopharmacology

individual indications, good clinical practice

through to the use of medications in

and optimal treatment and algorithms.

• 153 applications, 49 participants from

• 17 participants from 9 different

developing-economy countries

Organisation, facilities, registration,

tuition, accommodation and food

• 14 faculty from 7 countries

Focused training for developing European countries

Clinical training II Propagating best practices, training future clinical leaders

ECNP Seminars in Neuropsychopharmacology 23-25 March 2018, Volgograd, Russia

20-22 April 2018, Odessa, Ukraine 16-18 November 2018, St Petersburg, Russia

High-impact training courses for developingeconomy countries, to enhance knowledge and skills in a concentrated learning environment with local and international experts.

- Volgograd 67 participants
- Odessa: 56 participants
- St Petersburg: 48 participants

Funded by ECNP R&S.



BBSRC-ECNP Advanced Methods for Reproducible Science Workshop 3-8 April 2018, Windsor, United Kingdom

Five-day residential course on advanced methods for reproducible science to raise the awareness of methods and to improve reproducibility across scientific disciplines.

• 30 participants

10 European participants funded by ECNP R&S.

ECNP School of Child

and Adolescent 8-13 April 2018, Venice, Italy

psychiatrists.

- 26 countries
- economy countries
- 16 faculty from 6 countries

Registration, tuition, accommodation and food provided by ECNP R&S.

Neuropsychopharmacology

A week-long residential programme of intensive training in clinical neuropsychopharmacology for child and adolescent

• 122 applications, 47 participants from

• 16 participants from 10 developing/

"One of the most valuable and beautiful experiences of my life."

ECNP Small Private Online Course (SPOC): 'Introduction to Neuropsychopharmacology'

Online training course to prepare clinicians in ECNP educational activities, seminars, schools and internships.

- Modules covering neuroanatomy, neurophysiology, neurogenetics, psychopharmacology, immunology and statistics
- Due for release 2019

Funded by ECNP R&S.

Nearly 1,000 junior scientists pass through ECNP events every year'



Science

The ability to connect Europe's applied and translational neuroscience community - from basic research all the way to clinical practice - and help to make it greater than the sum of its parts is central to ECNP's reason for existence.



European

Neuropsychopharmacology

International journal in applied brain science,

encompassing basic and clinical and research on the effects of centrally acting agents in

ECNP Networks ECNP Networks

Virtual, multi-centre European research clusters for the collection and aggregation of continent-wide clinical data, and for fostering research collaboration and ideas-sharing across the translational neurosciences.

• 13 Networks, covering a range of disorders and methods • First Thematic Working Group (TWG) launched, on

Outreach

ECNP connects all of the key stakeholders in the CNS treatment arena, from researchers, to industry, regulators, policy-makers and patients – across the whole treatment cycle. Leveraging this position for the benefit of the field is a vital part of ECNP's advocacy and awareness-raising role.



ECNP New Frontiers

ECNP New Frontiers meeting on

Neurodevelopmental disorders

A unique platform for scientists, industry leaders

18-19 March 2018, Nice, France

Regulatory Spotlight Session

9 October 2018, Barcelona, Spain

A special regulatory dialogue session with the European Medicines Agency (EMA), designed for open and active engagement amongst EMA stakeholders.

- Development of medicines in child and adolescent psychiatry
- Covering regulatory, academic, and industry perspective

Speakers and eight regulator subsidies provided by 31st ECNP Congress Foundation



Treasurer's report

The fundamentals of ECNP's financial position remain strong, with the College enjoying a sound capital base, strong market presence, and a beneficial tax environment.

As forecast, however, ECNP and R&S both reported significant deficits this year. These were due in part to lower proceeds from the 30th ECNP Congress¹ (Paris being an especially expensive city), which were expected; and a significant end-of-year dip in the equities markets (and hence in investment income), which was not. The deficits are consistent with the College's policy of limiting capital accumulation, in keeping with the agreement with the Dutch tax authorities that underpins our tax-exempt status. We anticipate future deficits as we continue to bring our capital position into alignment with the agreed cap.

The key priorities going forward:

- Proactive tax and regulatory compliance
- Capital preservation at agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

1) Congress proceeds are booked in the year after the congress occurs.

Risks

ECNP is sustained by income from essentially two sources: fundraising at the ECNP Congress, and the proceeds of our investment portfolio; with additional revenue from membership subscriptions and the ECNP journal.

The investments

While the capital markets have been extremely effective generators of return over the long term, short-term results – especially since 2008 – have been highly unpredictable. Market volatility is hard enough to manage at the best of times, but because much of the instability since 2008 has been driven by geopolitical events rather than economic fundamentals, it has been especially difficult. ECNP is adjusting to this environment by continuously monitoring our investment strategy and recalibrating risk and return expectations on an ongoing basis.

The ECNP Congress

The congress is ECNP's largest and most complex activity, its most important in terms of projecting the ECNP mission, and its primary fundraising vehicle. Its ongoing health and vitality is therefore of vital interest to the College and risks surrounding it are carefully watched. These include:

• **Political disturbance.** ECNP has already experienced some of this, with the 2015 Paris terrorist attacks still to some extent reverberating during the 30th ECNP Congress in Paris in 2017, and, in a very different form, the effects of the 2017-18 Catalan separatist crisis on the 31st ECNP Congress in Barcelona. In both cases the impact, in terms of depressed registrations, was slight, but nevertheless provided examples of the congress's exposure to a generally less stable world.

- Climate reform. International congresses are heavily dependent on low-cost air travel. Swedish already has a word – *flygskam* – for "flight shame," reflecting a wider trend of changing attitudes to the sustainability of short-haul flights. If this feeling intensifies, it is reasonable to assume that at some point legislation will follow.
- Technological disruption. Congresses are a form of information technology, and informational technology is notoriously susceptible to seismic and often sudden disruption. While we believe there will always be a demand for face-to-face meetings, whether this demand will continue to be able to answer ECNP's fund-raising goals remains to be seen.
- Market shifts. International congresses have long served as important outreach vehicles for industry, and the revenue derived from these activities has helped to support the ECNP Congress's financial viability. It is the expectation that this support will decrease over time, as the economics of the industry change and the regulations governing continuing medical education (CME) become more restrictive. The continuing proliferation of meetings is also putting increased pressure on attendance and fragmenting audiences.

The journal

ECNP has enjoyed a 30-year relationship with Elsevier. The future of subscriptions journals, however – with the rise of open-access publishing, and especially Science Europe's proposed 'Plan S' – remains very unclear. However, although the renegotiation of the agreement in 2017 resulted in a considerably more favourable royalty arrangement for ECNP, the journal generates only a relatively small part of the College's overall income.

Membership

While membership numbers have remained broadly stable, changing demographics and consumer priorities have in general worked against the value traditionally accorded to membership of societies and associations. The College continues to work on this challenge. We see membership however as a good in itself, not as a source of income.

Future strategy

The College anticipates continuing deficits as it seeks to comply with the capital cap agreed with the Dutch tax authorities (a condition of ECNP Association's tax-exempt status) in 2012. The focus of this strategy will be on (a) time-bound expenditures, to avoid permanent, structural costs, and (b) investments in new areas of activity that will diversity the College's income base as a hedge against the risks outlined above. Time-bound expenditures include the co-morbidity study being conducted with the London School of Economics and Vienna Medical School, as well as the planned 'small private online course' (SPOC), an important new foray for ECNP into online education. Longerterm investments include the development of new delivery channels and the cultivation of a new audiences.

It is hoped that through these measures ECNP's long-term financial sustainability can be secured, and the College can continue to deliver its exceptional array of programmes without eroding its underlying capital reserves. Given the economic and political uncertainties ahead, this remains challenging. However, the College is confident that, to the extent it can be, it is prepared.

Eduard Vieta *Treasurer*

Financial statements

ECNP Association

Balance sheet as at 31 December 2018 (in €)

(after appropriation of profit/losses)

	31-12-2018		31-12-2017	
ASSETS				
CURRENT ASSETS				
Accounts receivable				
Debtors	4,740		398	
Amounts owed by other foundations	197,522		213,272	
Taxes	9,922		393	
Other accounts receivable	182,557		248,721	
		394,741		462,784
Securities		13,004,009		12,409,727
Bank Deposits		1,656,347		2,359,131
		15,055,097		15,231,642
EQUITY				
Other reserves		14,763,857		15,032,103
CURRENT LIABILITIES				
Trade creditors	227,779		106,157	
Taxes	4,250		-	
Other liabilities	59,211		93,382	
		291,240		199,539
		15,055,097		15,231,642

Statement of income and expeniture 2018

INCOME

Membership fees Royalties Interest and similar income

Total income

EXPENSES

Administration Other expenses Europoean Neuropsychopharmacology Other activities Interest and similar charges

Total expenses

Net result

Appropriation of result Other reserves

Balance 2018	Balance 2017
81,618	91,604
126,492	118,000
267,118	438,842
475,228	648,446
243,941	195,004
162,397	180,221
34,304	29,695
271,393	33,837
31,439	30,076
743,474	468,833
-268,246	179,613
-268,246	179,613

ECNP R&S

Balance sheet as at 31 December 2018 (in €)

(after appropriation of profit/losses)

	31-12-2018		31-12-2017	
ASSETS				
CURRENT ASSETS				
Accounts receivable				
Debtors	12,487		7,375	
Amounts owed by congress foundations	279,952		213,559	
Amounts owed by other foundations	4,250		-	
Taxes	6,099		4,854	
Other accounts receivable	68,808		109,431	
Prepayments and accrued income	39,466		45,564	
		411,062		380,783
Securities		8,870,862		8,357,789
Bank Deposits		4,108,011		4,873,073
		13,389,935		13,611,64
RESERVES, FUNDS AND LIABILITIES				
RESERVES AND FUNDS				
Other reserves	13,065,315		13,351,045	
Designated fund	-		55,506	
		13,065,315		13,406,55
CURRENT LIABILITIES				
Trade creditors	166,804		102,028	
Amounts owed by congress foundations	100,001		102,020	
and college	12,884		53,384	
Other liabilities	144,932		49,682	
		324,620		205,094

Statement of income and expeniture 2018

Interest and similar income Grants

Proceeds fundraising

Total income

INCOME

NbN books

EXPENSES

Meetings and other activities Other expenses Interest and similar charges

Total expenses

Net result

Appropriation of result

Other reserves Designated fund

Balance 2018	Balance 2017
384,311	444,374
55,360	94,989
166,883	267,620
11,134	-
617,688	806,983
666,868	599,369
269,332	231,244
22,724	-
958,924	830,613
-341,236	-23,630
-285,730	-23,630
-55,506	-
-341,236	-23,630

Executive Director's report

The ECNP Office operates an agency model, providing services to the constituent ECNP foundations. Its time is apportioned according to the ratios: 20% to ECNP Association, 20% to ECNP R&S, 60% to the ECNP Congress.

> The last couple of years have also seen the addition of a new category of 'clients' – European projects. As of 2018 the Office currently supports seven major Innovative Medicines Initiative (IMI) and Horizon 2020 projects with a variety of dissemination and organisational services. Configuring the Office to accommodate this additional activity, allowing in particular for the variances in its flow, remains an ongoing priority. A new member of staff, Maxime Besutti, has been recruited into our communications group to provide additional support in this area.

proud of their achievements.

Going forward, the focus of the Office will be on delivering the College's goals while necessarily working to contain costs.

Alexander Schubert Executive Director

ECNP is the largest non-institutional supporter of education and research in applied neuroscience in Europe

Meanwhile, the Office is also increasing its focus on the ECNP Congress. In 2008 management of the exhibition was brought inhouse, and the process begun of insourcing the entire congress registration apparatus, the last major piece of congress logistics currently contracted out. In doing so we believe we can not only achieve cost efficiencies, but - even more importantly - ensure a higher level of quality control and better service to our participants. The Office is also working on new initiatives to enhance the overall delegate experience, the results of which were seen at this year's Barcelona congress in, amongst others, the new 'Bubble' space, with its own mini-programme, and the highly successful 'Love Your Brain' campaign. These innovations are a tribute to the commitment and creativity of the ECNP Office staff, and I am extremely

Report of the ECNP Review Board

The duty of the ECNP Review Board (ERB) is to assess continuously not only the quality of the scientific activities, but the whole governance of the ECNP.

- The current composition of the ERB is:
- Chair: Hans-Jürgen Möller
- Members: Carlo Altamura, Naomi Fineberg, Kim Do

Kim Do followed Rafael Maldonado, who finished his term 2017. We thank him for his contributions!

The ERB usually has two meetings per year: we met at the occasion of the ECNP Workshop in Nice in March and at the beginning of the ECNP Congress.

Each of these meetings are associated with meetings between the ERB and the ECNP president and Executive Committee (EC) members.

The ERB meetings are full of intensive discussions and generate a lot of creative ideas and suggestions. The ECNP president and the EC-members were very open to listen to all the issues brought forward by the ERB.

It is outstanding what ECNP offers to its members and to the scientific community on different levels: annual congresses; smaller-sized and more targeted meetings, such as the Nice Workshop; educational meetings, among others on psychopharmacology (Oxford, Venice) or on methodology (Barcelona); research-oriented Networks to obtain (EU) funding; the ECNP journal (*European Neuropsychopharmacology*); the Neuroscience-based Nomenclature project, etc. All of these are on an excellent level and very well received.

The Neuroscience-based Nomenclature project, chaired by Joseph Zohar, was started by ECNP with further development including other relevant societies (CINP, ACNP, AsCNP). ECNP still has the lead.

The involvement of ECNP in the EU political scene is of the greatest importance for the development of our field, especially in terms of advocating for research funding.

The structure of ECNP and the related foundations is complex, but this reflects historical developments and tax-related necessities.

The whole governance of ECNP is in good order and very effective, among others due to the very competent and devoted administration in the Utrecht office.

ECNP together with the related foundations is in an outstanding financial situation. Its reserves provide a good buffer in the current difficult time of psychopharmacology.

ECNP has managed in the recent years to be more and more transparent for the members in terms of budgeting and its complex foundations structure.

The EC is fully aware of the current problems in psychopharmacology, especially those of the pharmaceutical industry, and how this will impact among others the support for congresses by the industry and finally the financial income of ECNP.

The EC has several ideas how to overcome these problems, among others by taking over more and more the congress organisation by the ECNP Office itself, by changing the focus more to neuroscience, and by trying to recruit other groups of participants, such as neurobiologically oriented psychologists.

The EC is open for other ideas, e.g. coming from the members, to prepare ECNP for the future and shape ECNP even more according to their needs.

The ERB brought forward the following suggestions, among others based on discussions with members, to the EC:

- ECNP should increase further the focus on gender-balance issues.
- ECNP should find ways to increase the active participation of scientists from middle and eastern Europe.
- ECNP should develop even more its role as scientific educator for clinicians, being the only society in Europe with this competency and mission.
- ECNP should consider the current misfit between the background of delegates (70% clinicians) and the objectives/activities of the organisation.
- It might be meaningful to give more people access to the Workshop on Clinical Research Methods and to implement new workshops, e.g. on preclinical research methodology.
- An increased involvement of neurologists and neuroscience-oriented psychologists seems advisable, not only for economic reasons, but also to enrich the scientific scope of ECNP.

Summary

- ECNP is in a very good shape under all aspects and very powerful.
- The whole governance is in optimal order and very effective.
- The planning for the future addresses well the upcoming challenges.


Hans-Jürgen Möller Chair

Governance

ECNP operates as an amalgamation of different entities. These entities are legally autonomous and self-sustaining, but each represents the ECNP brand and serves co-ordinated goals.

These entities are:

- The European College of Neuropsychopharmacology ("ECNP Association"), a Swiss-constituted member society permanently based in the Netherlands
- The ECNP Research and Scholarship Foundation ("ECNP R&S"), a Dutch-constituted foundation legally domiciled in the Netherlands
- The ECNP Congress Foundations, one per congress; Dutch-constituted foundations legally domiciled in the Netherlands
- The Stichting Buro ECNP, a Dutch-constituted foundation legally domiciled in the Netherlands



ECNP Association, ECNP R&S and the ECNP Congress Foundations are all public-interest-serving entities (algemeen nut beogende instellingen – 'ANBI') under Dutch tax law.

The Stichting Buro ECNP is the legal umbrella housing the ECNP Office.

Membership

842 members

- 439 supporting members
- 1,281 total members

Top ten countries:

- 1. United Kingdom
- 2. Germany
- 3. The Netherlands
- 4. Spain
- 5. Italy
- 6. Sweden
- 7. United States
- 8. Russia
- 9. France
- 10. Switzerland

Re-imbursement

ECNP Association

The presidency comes with a grant of \notin 15,000 and each officer position (vice president, president-elect, past president, secretary, treasurer) \notin 4,000 to assist with secretarial expenses, payable to their institution of primary employment. Each member of the Executive Committee receives a lump sum of \notin 1,500 to cover incidental expenses related to their role.

ECNP R&S

Members of the board do not receive remuneration for their role.

ECNP Congress Foundations

The chair of the Scientific Programme Committee receives € 6,000 for secretarial assistance, payable to his/her institution of primary employment. Other members of the Scientific Programme Committee receive € 1,000 for the duration of their term to cover associated expenses.

Stichting Buro ECNP

Members of the board do not receive remuneration for their role.

ECNP Association

Executive Committee 2016-2019

Celso Arango, Spain, President Gitte Moos Knudsen, Denmark, President-elect Laurence Lanfumey, France, Vice-president Guy Goodwin, United Kingdom, Past-president Martien Kas, the Netherlands, Secretary Eduard Vieta, Spain, Treasurer

Councillors

Elisabeth Binder, Germany Damiaan Denys, the Netherlands Suzanne Dickson, Sweden Catherine Harmer, United Kingdom Stefano Pallanti, Italy Gil Zalsman, Israel

Non-voting Members

Gerry Dawson, United Kingdom, Co-opt Member Joop van Gerven, the Netherlands, Co-opt Member Astrid Linthorst, United Kingdom, Chair Scientific Programme Committee 29th, 30th, 31st ECNP Congress Andreas Meyer-Lindenberg, Germany, Editor-in-Chief *European Neuropsychopharmacology* Mark J. Millan, France, Co-opt Member Andreas Reif, Germany, Chair Scientific Programme Committee 32nd, 33rd, 34th ECNP Congress Alexander Schubert, the Netherlands, Executive Director

Award Committee

Andreas Meyer-Lindenberg, Germany, Chair Monica DiLuca, Italy Raquel Gur, United States Wim van den Brink, the Netherlands

Communication Committee

Damiaan Denys, the Netherlands, Chair Andreas Meyer-Lindenberg, Germany (Editor-in-Chief ENP) Jaanus Harro, Estonia Kamilla Miskowiak, Denmark Iria Grande, Spain

ECNP Review Board

Hans-Jürgen Möller, Germany, Chair Carlo Altamura, Italy Kim O. Do, Switzerland Naomi Fineberg, United Kingdom

Nominating Committee (for the 2019-2021 Executive Committee)

Guy Goodwin, United Kingdom, past President, Chair Celso Arango, Spain, President Tomas Hökfelt, Sweden Gitte Knudsen, Denmark, President-elect Ruth McKernan, United Kingdom Hans-Jürgen Möller, Germany Wim van den Brink, the Netherlands

European Neuropsychopharmacology Editorial Board

Andreas Meyer-Lindenberg, Germany, Editor-in-Chief Michael Davidson, Israel Jaanus Harro, Estonia Rafael Maldonado, Spain Brian Morris, United Kingdom Andreas Reif, Germany Thomas. G. Schulze, Germany Eduard Vieta, Spain

ECNP R&S

Board 2016-2019

Celso Arango, Spain, Chair Gitte Moos Knudsen, Denmark, Secretary Eduard Vieta, Spain, Treasurer

Early Career Advisory Panel (ECAP)

Marin Jukic, Sweden, Chair Alla Chistol, Republic of Moldova Judith Harrison, United Kingdom Aiste Lengvenyte, Lithuania Nils Opel, Germany Guy Goodwin, United Kingdom, representative Executive Committee

ECNP Networks Board

Gitte Moos Knudsen, Denmark, Chair Nic van der Wee, the Netherlands, Scientific Co-ordinator

ECNP Networks Taskforce

ADHD: Barbara Franke, the Netherlands; Andreas Reif, Germany Anxiety Disorders (ADRN): Borwin Bandelow, United Kingdom; Katharina Domschke, Germany *Bipolar Disorders (ENBREC):* Michael Bauer, Germany; Lars Kessing, Germany; Ole Andreassen, Norway Child and Adolescent Neuropsychopharmacology: Alessandro Zuddas, Italy; Carmen Moreno, Spain Down Syndrome and Other Genetic Development Disorders (DSG2D): Marie-Claude Potier, France; Mara Dierssen, Spain Experimental Medicines: Gerry Dawson, United Kingdom *Neuroimaging:* Hilleke Hulshoff Pol, the Netherlands; Nikolaos Koutsouleris, Germany Nutrition: Suzanne Dickson, Sweden; Roger Adan, the Netherlands Obsessive Compulsive and Related Disorders (OCRN): José Manuel Menchón, Spain Preclinical Data Forum: Anton Bespalov, Germany; Thomas Steckler, Belgium Schizophrenia: Silvana Galderisi, Italy; István Bitter, Hungary Suicide: Danuta Wasserman, Sweden; Vladimir Carli, Sweden Traumatic Stress: Eric Vermetten, the Netherlands; Joseph Zohar, Israel Prevention of mental disorders and mental health promotion (TWG): Paolo Fusar-Poli, United Kingdom/ Italy

Educational Committee

Gil Zalsman, Israel, Chair Avraham Avital, Israel Katharina Domschke, Germany Guy Goodwin, United Kingdom Livia de Picker, Belgium Ekin Sönmez, Turkey

Neuroscience-based Nomenclature Task Force

Joseph Zohar, Israel, Chair Pierre Blier, Canada Filippo Drago, Italy Guy Goodwin, United Kingdom David Kupfer, United States Hans-Jürgen Möller, Germany David Nutt, United States Stephen Stahl, United States Hiroyuki Uchida, Japan Shigeto Yamawaki, Japan

New Frontiers Meeting Committee

Celso Arango, Spain, Chair Gerry Dawson, United Kingdom Hilkka Kärkkäinen, GAMIAN-Europe, Finland Martien Kas, the Netherlands Stephen R. Marder, United States Hugh Marston, United Kingdom Luca Pani, United States Stephane Pollentier, Germany Thomas Steckler, Belgium

Workshop Committee

Martien Kas, the Netherlands, Chair Roger Adan, the Netherlands Elisabeth Binder, Germany Suzanne Dickson, Sweden Katharina Domschke, Germany Catherine Harmer, United Kingdom Jaanus Harro, Estonia Marin Jukic, Sweden Gitte Knudsen, Denmark Oscar Marin, Spain Mark Millan, France Andreas Reif, Germany

31st ECNP Congress Foundation

Board

Celso Arango, Spain, Chair and Treasurer Alexander Schubert, the Netherlands, Secretary Astrid Linthorst, United Kingdom

Scientific Programme Committee

Astrid Linthorst, United Kingdom, Chair Josefina Castro-Fornieles, Spain Kim Do, Switzerland Joop van Gerven, the Netherlands Jeremy Hall, United Kingdom Marion Leboyer, France Paul Lucassen, the Netherlands Andreas Meyer-Lindenberg, Germany, Editor-in-Chief *European Neuropsychopharmacology* Kamilla Miskowiak, Denmark Agneta Nordberg, Sweden Stefano Pallanti, Italy Andreas Reif, Germany Marco Riva, Italy Rainer Spanagel, Germany Mark Weiser, Israel Aysegul Yildiz, Turkey Gil Zalsman, Israel, Chair ECNP Educational Committee

Scientific Advisory Panel for 2017-2020

Roger Adan, the Netherlands Laura Airas, Finland Pino Alonso, Spain Frank Bellivier, France Anton Y. Bespalov, Germany István Bitter, Hungary Michael Bloomfield, United Kingdom Jan Booij, the Netherlands Jan K. Buitelaar, the Netherlands Jocelyne Caboche, France Josefina Castro-Fornieles, Spain Annamaria Cattaneo, United Kingdom Ginetta Collo, Italy Andrea Danese, United Kingdom Andrea de Bartolomeis, Italy Suzanne L. Dickson, Sweden Katharina Domschke, Germany Filippo Drago, Italy Anne Eckert, Switzerland Angelika Erhardt, Germany Mia Ericson, Sweden Karen Ersche, United Kingdom David P. Finn, Ireland Gabriele Fischer, Austria Kevin C.F. Fone, United Kingdom Barbara Franke, the Netherlands Christine Freitag, Germany Vibe G. Frokjaer, Denmark Silvana Galderisi, Italy Alexander Gerhard, United Kingdom Mark A. Geyer, United States Philip Gorwood, France Iria Grande, Spain Edna Grünblatt, Switzerland Antoni Gual, Spain Gregor Hasler, Switzerland Martin Hatzinger, Switzerland Judith Homberg, the Netherlands liris Hovatta, Finland Michal Hrdlicka, Czech Republic Evgeny Krupitsky, Russia Marion Leboyer, France Klaus-Peter Lesch, Germany Stefan Leucht, Germany Paul John Lucassen, the Netherlands Anabel Martinez-Aran, Spain

David Mataix-Cols, Sweden Raymond Mongeau, France Carmen Moreno, Spain Arne Mørk, Denmark Rainald Mössner, Germany Dieter Naber, Germany Inga Neumann, Germany Florence Noble, France Mariusz Papp, Poland Mara Parellada, Spain Walter Pirker, Austria Edith Pomarol-Clotet, Spain Marie-Claude Potier, France Christopher Pryce, Switzerland Andreas Reif, Germany Emma Robinson, United Kingdom Michelle Roche, Ireland Henricus G. Ruhe, the Netherlands Rainer Rupprecht, Germany Janusz K. Rybakowski, Poland David A. Slattery, Germany Iris E.C. Sommer, the Netherlands Daniel Souery, Belgium Florence Thibaut, France Marta Torrens, Spain Elizabeth Tunbridge, United Kingdom Wim van den Brink, the Netherlands Guido van Wingen, the Netherlands Louk J. Vanderschuren, the Netherlands Elisabet Vilella, Spain Odile Viltart, France Ina Weiner, Israel Abraham Weizman, Israel Sue Wilson, United Kingdom Aysegül Yildiz, Turkey Alessandro Zuddas, Italy Koen Schruers, the Netherlands

Stichting Buro ECNP

Board

Celso Arango, Chair Martien Kas, Secretary/Treasurer

ECNP Office

Alexander Schubert, Executive Director Iris Allebrandi, Director Congresses & Meetings Ellen van den Berg, Director Operations Ligia Bohn, Senior Project Manager Communication Godelieve Escartín, Senior Project Manager Congresses & Meetings Eline Dimmendaal, Project Manager Congresses & Meetings Annemieke Heuvink, Project Manager Congresses & Meetings Melinda Spitzer, Project Manager Congresses & Meetings Corine ten Brink, Project Manager Science & Education Wendy Schouten, Project Manager Science & Education Petra Hoogendoorn, Project Manager Science, Education & Communication Matteo Bason, Scientific Co-ordinator Vandana Kamath, Assistant Project Manager Communication Maxime Besutti, Assistant Project Manager Communication Rilana Rahaël, Financial Administrative Assistant

Key Identification Numbers

ECNP Association VAT number: NL823523974B01 RSIN: 823523974 R&S

ECNP R&S

VAT number: NL807967087B01 RSIN: 807967087 Chamber of commerce number: 41215196



ECNP Office T: +31 88 75 69 555 E: secretariat@ecnp.eu www.ecnp.eu

Postal Address PO Box 85410 3508 AK Utrecht The Netherlands

Visiting Address Bolognalaan 28 3584 CJ Utrecht The Netherland



© 2019 European College of Neuropsychopharmacology